Homocysteine and diabetes: Role in macrovascular and microvascular complications.
Cardiovascular disease
Diabetes mellitus
Homocysteine
Macrovascular complications
Microvascular complications
Journal
Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
08
10
2020
revised:
23
11
2020
accepted:
17
12
2020
pubmed:
10
1
2021
medline:
13
1
2022
entrez:
9
1
2021
Statut:
ppublish
Résumé
Diabetes mellitus (DM) can lead to the development of macro- and microvascular complications. Homocysteine (Hcy) may play a role in the development of cardiovascular (CV) diseases (CVDs). The role of Hcy in the development of the vascular complications associated with DM is not clearly defined. Despite a strong initial assumption regarding the importance of Hcy in DM and its complications, over time "enthusiasm has waned" because several studies showed unconvincing and occasionally contradictory results. A universal conclusion is not easy to draw given the diversity of studies (e.g. number of patients, design, folic acid and vitamin B status, ethnic differences, genetic background). For some complications, most results encourages further investigation. Impaired renal function is a major independent determinant of high total Hcy (tHcy) levels. However, the role of hyperhomocysteinaemia (HHcy) in the development of diabetic kidney disease (DKD) has yet to be determined. Hcy-lowering therapies can significantly decrease Hcy levels but their effects on CVD risk reduction are conflicting. Further studies are needed to determine the influence of Hcy-lowering therapy on CVD risk reduction, especially in patients with DM.
Identifiants
pubmed: 33419630
pii: S1056-8727(20)30635-8
doi: 10.1016/j.jdiacomp.2020.107834
pii:
doi:
Substances chimiques
Homocysteine
0LVT1QZ0BA
Folic Acid
935E97BOY8
Vitamin B 12
P6YC3EG204
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107834Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest EM has given talks or attended conferences sponsored by Novo Nordisk, SANOFI, AstraZeneca, SERVIER, MSD and Amgen. IK has given talks or attended conferences sponsored by Abbott Laboratories, Eli Lilly, Novo Nordisk, Pfizer, Pliva, Berlin-Chemie and Boehringer Ingelheim. MS has given talks or attended conferences sponsored by Novo Nordisk, Amgen, Pfizer, Pliva, Berlin-Chemie and Boehringer Ingelheim. SD has given talks or attended conferences sponsored by Boehringer Ingelheim, Astra Zeneca, Servier, Sanofi. DPM has given talks, acted as a consultant or attended conferences sponsored by Amgen, Novo Nordisk and Libytec.